Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

abbvie limited - brimonidine tartrate 1.5 mg/ml;   - eye drops, solution - 1.5 mg/ml - active: brimonidine tartrate 1.5 mg/ml   excipient: boric acid calcium chloride dihydrate carmellose sodium hydrochloric acid magnesium chloride hexahydrate potassium chloride purified water sodium borate pentahydrate sodium chloride sodium chlorite as purite sodium hydroxide - alphagan® p 1.5 eye drops are effective for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 1.5 mg/ml - eye drops, solution - excipient ingredients: magnesium chloride hexahydrate; boric acid; sodium chlorite; sodium chloride; carmellose sodium; borax; sodium hydroxide; purified water; hydrochloric acid; potassium chloride; calcium chloride dihydrate - alphagan p 1.5 eye drops are effective in lowering elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. alphagan p 1.5 eye drops can be used in the treatment of glaucoma as either monotherapy or in combination with topical beta blockers.

Belgia - inglise - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - brimonidine tartrate 2 mg/ml - eq. brimonidine 1,3 mg/ml; timolol maleate 6,8 mg/ml - eq. timolol 5 mg/ml - eye drops, solution - 2 mg/ml - 5 mg/ml - brimonidine tartrate 2 mg/ml; timolol maleate 6.8 mg/ml - timolol

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate 2 mg in 1 ml - brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. the lop lowering efficacy of brimonidine tartrate ophthalmic solution 0.2% diminishes over time in some patients. this loss of effect appears with a variable time of onset in each patient and should be closely monitored. brimonidine tartrate ophthalmic solution 0.2% is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. it is also contraindicated in patients receiving monoamine oxidase (mao) inhibitor therapy.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate 1.5 mg in 1 ml - brimonidine tartrate ophthalmic solution, 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. brimonidine tartrate ophthalmic solution, 0.15% is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. it is also contraindicated in patients receiving monoamine oxidase (mao) inhibitor therapy.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

sandoz inc - brimonidine tartrate (unii: 4s9cl2dy2h) (brimonidine - unii:e6gnx3hhte) - brimonidine tartrate 1.5 mg in 1 ml - brimonidine tartrate ophthalmic solution, 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. brimonidine tartrate ophthalmic solution, 0.15% is contraindicated in patients with hypersensitivity to any component of this product. reproductive studies performed in rats and rabbits with oral doses of 0.66 mg base/kg revealed no evidence of harm to the fetus due to brimonidine tartrate ophthalmic solution, 0.15%. dosing at this level produced an exposure in rats and rabbits that is 80 and 40 times higher than the exposure seen in humans, respectively. there are no adequate and well-controlled studies in pregnant women. in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent. brimonidine tartrate ophthalmic solution, 0.15% should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. it is not known whether this drug is excreted in h

Malta - inglise - Medicines Authority

allergan pharmaceuticals ireland castlebar road, westport, county mayo, ireland - brimonidine tartrate, timolol - eye drops, solution - brimonidine tartrate 2 mg/ml timolol 5 mg/ml - ophthalmologicals

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - brimonidine tartrate, quantity: 1.5 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; potassium chloride; borax; sodium hydroxide; sodium chlorite; purified water; calcium chloride dihydrate; boric acid; carmellose sodium; hydrochloric acid; magnesium chloride hexahydrate - enidin p 1.5 eye drops are effective in lowering elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. enidin p 1.5 eye drops can be used in the treatment of glaucoma as either monotherapy or in combination with topical beta blockers.

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - brimonidine tartrate 1.5 mg/ml - eye drops, solution - 1.5 mg/ml - active: brimonidine tartrate 1.5 mg/ml excipient: borax boric acid calcium chloride dihydrate carmellose sodium hydrochloric acid magnesium chloride hexahydrate potassium chloride purified water sodium chloride sodium chlorite as purite sodium hydroxide - enidin® p 1.5 eye drops are effective for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

allergan pharmaceuticals ireland - brimonidine tartrate; timolol maleate - eye drops, solution - 2 mg/ml + 5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations